[Venetoclax Combined with Dose-reduced HAD As Induction Treatment for Patients with De-novo Acute Myeloid Leukemia]

Overview

Journal Zhonghua Xue Ye Xue Za Zhi

Specialty Hematology

Date 2024 Jul 1

PMID 38951068

Authors

Z S Yan

Y Li

B Zhang

J S He

J S Li

S N Wei

Q Wang

Q L Li

K Q Liu

Y C Mi

Affiliations

Soon will be listed here.

Abstract

The efficacy and safety of venetoclax combined with reduced dose HAD regimen in the treatment of newly diagnosed acute myeloid leukemia (AML) was investigated. From May 2022 to January 2023, a total of 25 patients with newly diagnosed AML were treated with venetoclax combined with reduced-dose HAD regimen as induction therapy. Accoding to the 2017 ELN recommendations, 13 (52.0%) in favoable, 3 (12.0%) in intemediate, and 9 (36.0%) in adverse. The ORR (CR rate+PR rate) was 88.0%, and the CR rate was 84.0%. By May 30, 2023, with a median follow-up of 9 months, 1 year overall survival, event-free survival, and relapse-free survival were 100%, 94.7%, and 94.7%, respectively. All patients received 1-5 cycles of consolidation therapy and two median cycles. Treatment with venetoclax and reduced dose of HAD regimen in the treatment of patients with newly diagnosed AML was high effective and safe.

References

Griffioen M, De Leeuw D, Janssen J, Smit L . Targeting Acute Myeloid Leukemia with Venetoclax; Biomarkers for Sensitivity and Rationale for Venetoclax-Based Combination Therapies. Cancers (Basel). 2022; 14(14). PMC: 9318140. DOI: 10.3390/cancers14143456. View

Wei A, Montesinos P, Ivanov V, DiNardo C, Novak J, Laribi K . Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial. Blood. 2020; 135(24):2137-2145. PMC: 7290090. DOI: 10.1182/blood.2020004856. View

Jin J, Wang J, Chen F, Wu D, Hu J, Zhou J . Homoharringtonine-based induction regimens for patients with de-novo acute myeloid leukaemia: a multicentre, open-label, randomised, controlled phase 3 trial. Lancet Oncol. 2013; 14(7):599-608. DOI: 10.1016/S1470-2045(13)70152-9. View

. [Chinese guidelines for the diagnosis and treatment of adult acute myeloid leukemia (not APL) (2021)]. Zhonghua Xue Ye Xue Za Zhi. 2021; 42(8):617-623. PMC: 8501285. DOI: 10.3760/cma.j.issn.0253-2727.2021.08.001. View

Chua C, Roberts A, Reynolds J, Fong C, Ting S, Salmon J . Chemotherapy and Venetoclax in Elderly Acute Myeloid Leukemia Trial (CAVEAT): A Phase Ib Dose-Escalation Study of Venetoclax Combined With Modified Intensive Chemotherapy. J Clin Oncol. 2020; 38(30):3506-3517. DOI: 10.1200/JCO.20.00572. View

Zhao J, Agarwal S, Ahmad H, Amin K, Bewersdorf J, Zeidan A . A review of FLT3 inhibitors in acute myeloid leukemia. Blood Rev. 2021; 52:100905. PMC: 9846716. DOI: 10.1016/j.blre.2021.100905. View

Burchert A, Bug G, Fritz L, Finke J, Stelljes M, Rollig C . Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With -Internal Tandem Duplication Mutation (SORMAIN). J Clin Oncol. 2020; 38(26):2993-3002. DOI: 10.1200/JCO.19.03345. View

DiNardo C, Pratz K, Pullarkat V, Jonas B, Arellano M, Becker P . Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2018; 133(1):7-17. PMC: 6318429. DOI: 10.1182/blood-2018-08-868752. View

Suo X, Zheng F, Wang D, Zhao L, Liu J, Li L . Venetoclax combined with daunorubicin and cytarabine (2 + 6) as induction treatment in adults with newly diagnosed acute myeloid leukemia: a phase 2, multicenter, single-arm trial. Exp Hematol Oncol. 2023; 12(1):45. PMC: 10176670. DOI: 10.1186/s40164-023-00409-y. View

10.

DiNardo C, Jonas B, Pullarkat V, Thirman M, Garcia J, Wei A . Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. N Engl J Med. 2020; 383(7):617-629. DOI: 10.1056/NEJMoa2012971. View

11.

Stone R, Mandrekar S, Sanford B, Laumann K, Geyer S, Bloomfield C . Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation. N Engl J Med. 2017; 377(5):454-464. PMC: 5754190. DOI: 10.1056/NEJMoa1614359. View

12.

Kantarjian H, OBrien S, Jabbour E, Barnes G, Pathak A, Cortes J . Effectiveness of homoharringtonine (omacetaxine mepesuccinate) for treatment of acute myeloid leukemia: a meta-analysis of Chinese studies. Clin Lymphoma Myeloma Leuk. 2014; 15(1):13-21. DOI: 10.1016/j.clml.2014.09.011. View

13.

DiNardo C, Lachowiez C, Takahashi K, Loghavi S, Xiao L, Kadia T . Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia. J Clin Oncol. 2021; 39(25):2768-2778. PMC: 8407653. DOI: 10.1200/JCO.20.03736. View

14.

Wang H, Mao L, Yang M, Qian P, Lu H, Tong H . Venetoclax plus 3 + 7 daunorubicin and cytarabine chemotherapy as first-line treatment for adults with acute myeloid leukaemia: a multicentre, single-arm, phase 2 trial. Lancet Haematol. 2022; 9(6):e415-e424. DOI: 10.1016/S2352-3026(22)00106-5. View

15.

Wei H, Wang Y, Gale R, Lin D, Zhou C, Liu B . Randomized Trial of Intermediate-dose Cytarabine in Induction and Consolidation Therapy in Adults with Acute Myeloid Leukemia. Clin Cancer Res. 2020; 26(13):3154-3161. DOI: 10.1158/1078-0432.CCR-19-3433. View

16.

Kadia T, Reville P, Borthakur G, Yilmaz M, Kornblau S, Alvarado Y . Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial. Lancet Haematol. 2021; 8(8):e552-e561. PMC: 8884174. DOI: 10.1016/S2352-3026(21)00192-7. View

17.

Dohner H, Estey E, Grimwade D, Amadori S, Appelbaum F, Buchner T . Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2016; 129(4):424-447. PMC: 5291965. DOI: 10.1182/blood-2016-08-733196. View